GBI Research, a leading business
intelligence provider, has released its latest research, “Contraceptives
Market to 2018 – Safety Concerns Plague Drospirenone-containing Birth
Control Pills and Long-term Use of Estrogen”, which provides insights into the
global contraceptives market and market forecasts until 2018. The report
provides an in-depth analysis of the most commonly used contraceptives, such as
oral, topical, and injectable contraceptives, and devices such as intrauterine
devices, condoms, and vaginal rings. The report also examines the usage
patterns and annual cost of usage for these segments. It also includes insights
into the contraceptives R&D product pipeline and explores the competitive
landscape, including major companies in the contraceptives market. Finally, the
report also includes analysis of the mergers and acquisitions (M&A) and
licensing agreements that have taken place in the global contraceptives market.
The contraceptives
market is growing, and more than 90 million people from seven major markets
used them in 2011, with more than 24 million people having used them in the US
alone. The user population is expected to grow gradually during the forecast
period and reach more than 94 million in 2018.
According to GBI Research’s
analysis, in 2011, the contraceptives market was worth $10.2 billion,
indicating a Compounded Annual Growth Rate (CAGR) of 2.7% between 2004 and
2011. By 2018, the market is expected to reach $11.8 billion, growing at a CAGR
of 2.1%. The launch of the FC patch, AG200-15, Savvy Gel, LNG 20, Pill-Plus and
some key products in the late stage pipeline combined with increasing awareness
are expected to drive the market.
The annual cost of usage for
contraceptives was $113 in 2011, which grew from $104 in 2004 at a CAGR of
1.2%. This is expected to grow to $125 in 2018, at a CAGR of 1.4% between 2011
and 2018. The growth rate can be attributed to factors such as the expected
patent expiry of Mirena and Yaz. In the forecast period, CSD500, a condom
manufactured by Futura Medical and licensed to Reckitt and Benckiser, is
expected to strengthen the condom market.
The report is built using data and
information sourced from proprietary databases, primary and secondary research,
and in-house analysis by GBI Research’s team of industry experts.
Scope
- Data and analysis on the
contraceptives market in leading geographies: the US, the UK, Germany, France,
Italy, Spain and Japan; along with their reach in emerging markets.
- Annualized market data for oral contraceptives, topical contraceptives, injectable contraceptives, condoms, intrauterine devices and vaginal rings in the contraceptives market from 2004-2011, with forecasts to 2018.
- Market data on the therapeutic landscape, which covers oral, topical and injectable contraceptives, and includes market revenues, treatment usage patterns and the annual cost of usage.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the contraceptives market, which includes companies such as Bayer, Merck, Church & Dwight, Warner Chilcott Company, and Pfizer.
- Key M&A activities and licensing agreements that took place from 2008-2012 in the contraceptives market.
- Annualized market data for oral contraceptives, topical contraceptives, injectable contraceptives, condoms, intrauterine devices and vaginal rings in the contraceptives market from 2004-2011, with forecasts to 2018.
- Market data on the therapeutic landscape, which covers oral, topical and injectable contraceptives, and includes market revenues, treatment usage patterns and the annual cost of usage.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the contraceptives market, which includes companies such as Bayer, Merck, Church & Dwight, Warner Chilcott Company, and Pfizer.
- Key M&A activities and licensing agreements that took place from 2008-2012 in the contraceptives market.
Buy your copy of this
report @ http://www.rnrmarketresearch.com/contraceptives-market-to-2018-safety-concerns-plague-drospirenone-containing-birth-control-pills-and-long-term-use-of-estrogen-market-report.html
Reasons to buy
-
Align your product portfolio to markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Devise a more specifically-tailored country strategy through understanding of the key drivers and barriers in the contraceptives market of all the major countries.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Devise a more specifically-tailored country strategy through understanding of the key drivers and barriers in the contraceptives market of all the major countries.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Report Details:
Published: Nov 2012
No. of pages:85
Price: Single User License: US $3500
No comments:
Post a Comment
Note: only a member of this blog may post a comment.